NCT07648745 Cediranib Intestinal Obstruction Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07648745 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 7 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07648745 is a hot trial to watch
Intestinal Obstruction is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07648745 is notable because it evaluates Cediranib in a Phase 2 design sponsored by The University of Manchester. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07648745 |
| Official title | Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer (CEBOC) |
| Phase / status | Phase 2 / Completed |
| Intervention | Cediranib |
| Sponsor | The University of Manchester |
| Geography | United Kingdom |
| Enrollment | [object Object] |
| Primary endpoint | The number of patients free of grade III-V gastrointestinal perforation or fistula causally related to cediranib. |
| Endpoint time frame | From date of registration until 28 days after the last dose of cediranib, or until death, whichever occurs first. Minimum assessment period: 18 weeks of cediranib treatment or until prior withdrawal/death. |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
Ovarian cancer can often grow and cause obstructions in the bowel. These obstructions usually cannot be removed with surgery and can be fatal. This trial is testing whether a drug called cediranib can be used safely together with paclitaxel chemotherapy to treat ovarian cancer in women at risk of bowel obstructions. All participants will receive the cediranib/paclitaxel combination, and if the cancer worsens the participant will stop receiving paclitaxel and may receive an additional drug, olaparib, together with cediranib.
Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment. Planned enrollment of [object Object] participants across United Kingdom shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- The number of patients free of grade III-V gastrointestinal perforation or fistula causally related to cediranib. (From date of registration until 28 days after the last dose of cediranib, or until death, whichever occurs first. Minimum assessment period: 18 weeks of cediranib treatment or until prior withdrawal/death.) — The number of patients free of grade III-V gastrointestinal perforation or fistula during cediranib treatment. This is causally related to cediranib or the cediranib olaparib combination, during cediranib treatment until patient withdraws, dies or has been treated with cediranib for at least 18 weeks, and for 28 days following the last dose. The proportion will be calculated with an exact 95% confidence interval (CI)
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Cediranib is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: The University of Manchester is resolved to a normalized organization record in United Kingdom. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07648745 provides a focused lens on Intestinal Obstruction development. Its value will be determined by whether Cediranib can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
